Pay in 4 interest-free payments of $7.36 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
Inhibiting ferroptosis may help improve the structure and function of the kidney
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial
Customers who are not medically approved should receive a refund of the applicable initial payment, according to the websites stated process
These findings suggest that the sensitive populations for immunotherapy in the neoadjuvant setting may differ between HR+ and TNBC patients
US$ 20.16
US$ 29.57
US$ 20.17
US$ 23.87
US$ 29.81
US$ 26.27
US$ 28.41
